PharmiWeb.com - Global Pharma News & Resources
21-May-2024

Cambridge Cognition enhances commercialisation focus with appointment of Business Development VP

Cambridge, UK: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the appointment of Charlie Mains as VP of Business Development, where he will play a critical role in strengthening its pipeline of potential opportunities as the Group continues to focus on driving commercialisation across the business. 

  

Charlie joins Cambridge Cognition with a wealth of sector experience, having worked in the clinical trial technology industry for over 20 years. Charlie previously held the role of Senior Director of Strategic Alliances at Thread, a research platform which supports pharma organisations to capture data around in-clinic visits, and as the Senior Director of Business Development for CRF Health’s Strategic Accounts Group.

 

Charlie’s experience will prove invaluable for Cambridge Cognition as the Group continues to focus on delivering profitable growth and the provision of world-leading CNS clinical trials.

 

Alex Livingstone-Learmonth, Chief Commercial Officer at Cambridge Cognition commented:

“I am extremely excited to welcome Charlie to the Cambridge Cognition team at this critical phase in our growth trajectory. Charlie’s leadership skills, significant expertise and successful track record make him the ideal candidate to accelerate our Business Development activities, as we continue to drive growth and develop our significant pipeline of new opportunities.”

 

Charlie Mains, VP of Business Development at Cambridge Cognition, commented:

“I am thrilled to be joining Cambridge Cognition at this exciting time in the company’s growth journey. Within the dynamic world of CNS research, I am confident that I will be able to leverage my wealth of experience to the benefit of the wider team, and help to continue to develop the pipeline. I look forward to joining the team to support Cambridge Cognition’’s growth and, ultimately, help improve CNS research worldwide.”

Editor Details

  • Company:
    • Cambridge Cognition Holdings plc
  • Name:
    • Cambridge Cognition Holdings plc
Last Updated: 21-May-2024